Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor
about
Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast CancerPI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancerSoluble bone-derived osteopontin promotes migration and stem-like behavior of breast cancer cellsBuparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts.Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumorsGenetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomasNeural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases.Establishment of a novel retinoblastoma (Rb) nude mouse model by intravitreal injection of human Rb Y79 cells - comparison of in vivo analysis versus histological follow upSystemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.AKT signaling in ERBB2-amplified breast cancer.Preclinical HER-2 Vaccines: From Rodent to Human HER-2Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors.Blood-brain barrier remodeling during brain metastasis formation.Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.Role of the blood-brain barrier in the formation of brain metastases.Targeting PI3K in Cancer: Any Good News?Preclinical vaccines against mammary carcinoma.Mimicking breast cancer-induced bone metastasis in vivo: current transplantation models and advanced humanized strategies.Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine.PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures.Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.Efficacy of buparlisib in treating breast cancer.
P2860
Q26777734-31967B74-AD3D-41FE-AB1E-7BC2FC2C80C7Q27006181-27FFD42F-B82C-462C-B34D-E1E2BBEEE55EQ33675150-6C236AF6-A1A8-44A3-AE9E-21DE85A57950Q34461019-CE1738B3-EF04-4A33-A3E1-E33DA6BFB6F4Q34473478-17D7643D-D6AA-4D56-9DA3-DCBAE60E38FBQ34574879-AB713FC7-972B-45CC-BDE7-7E0E1D8B2CD0Q35051964-9C9A3614-6268-466B-8F66-A304035FB84DQ35067979-FFB247A3-B2A3-4739-831A-FF7EFA12B7F1Q36083446-BB789FAF-605A-44E4-815D-1B5C0FA7DFA3Q36150685-DA5D429D-D700-4BD3-958F-E9E508899180Q36544212-83107CFA-E70D-46B5-BD20-A426EE7CEA22Q36563578-ABCFD801-0D18-459B-861E-D76840B3597BQ36914661-6D6F9A89-D8EA-4EED-AAAD-08CF733B17CFQ37011768-3DEB9983-A8C0-47C6-B64A-4B39B8852129Q37217055-E9F847F8-CAC9-409F-B95D-1C1859936A2AQ37691212-E4D5FCE2-87C5-4087-807C-3CB4C858309DQ38076279-3350E390-9BE8-4DB9-8338-12C87BD8CF07Q38105322-1A2B2DBC-16C4-4C59-A83B-4EBB28755B96Q38160252-B0D7F6F1-3AE8-437F-BCE6-62DB11F5DED0Q38207530-25D12407-5826-490F-8CCE-B19D2CD0765AQ38238598-0BE4950C-FD6F-4735-8FE9-5640FD94B55BQ38259259-0EB4A130-E88C-4654-83C9-323A356004BFQ38575259-3A6428CB-5753-4317-A4C1-151E752F4339Q39226360-3ABAECFD-5FF8-40E0-B510-70E7B1F9C915Q42454757-853D6443-FCAB-4498-8F24-AF391E4212A8Q47169310-1E1BA0F5-26F0-4F64-9E52-8826FCE0B99DQ47938353-6D02889F-7141-4353-AABB-1C5C82F38E5CQ49711965-1D353458-FAB2-44F0-AA0F-8018BD031C2C
P2860
Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor
description
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
article publié dans la revue scientifique PLoS ONE
@fr
artículu científicu espublizáu en 2012
@ast
im Januar 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 2012)
@en
vedecký článok (publikovaný 2012)
@sk
vědecký článek publikovaný v roce 2012
@cs
wetenschappelijk artikel (gepubliceerd in 2012)
@nl
наукова стаття, опублікована у 2012
@uk
name
Multiorgan metastasis of human ...... treatment with PI3K inhibitor
@ast
Multiorgan metastasis of human ...... treatment with PI3K inhibitor
@en
Multiorgan metastasis of human ...... treatment with PI3K inhibitor
@nl
type
label
Multiorgan metastasis of human ...... treatment with PI3K inhibitor
@ast
Multiorgan metastasis of human ...... treatment with PI3K inhibitor
@en
Multiorgan metastasis of human ...... treatment with PI3K inhibitor
@nl
prefLabel
Multiorgan metastasis of human ...... treatment with PI3K inhibitor
@ast
Multiorgan metastasis of human ...... treatment with PI3K inhibitor
@en
Multiorgan metastasis of human ...... treatment with PI3K inhibitor
@nl
P2093
P2860
P50
P3181
P1433
P1476
Multiorgan metastasis of human ...... treatment with PI3K inhibitor
@en
P2093
Annalisa Murgo
Arianna Palladini
Carla De Giovanni
Emmanuelle di Tomaso
Giordano Nicoletti
Lorena Landuzzi
Marianna L Ianzano
Valentina Grosso
Valeria Stivani
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0039626
P407
P577
2012-06-21T00:00:00Z